Image-Based AI Touted as a New Weapon Against Rare Cancers
Studies by Paige demonstrate the greater accuracy that artificial intelligence potentially offers for pathologists
Emerging Tests-dtet
Diagnostics Pipeline: Roche’s New Cobas Liat Panel Can Test for Multiple STIs Simultaneously
The PCR-driven test provides results in about 20 minutes in non-laboratory settings
New and Improved: The Latest Research in Disease Screening
New ideas and innovations look beyond conventional screening options to facilitate improved disease diagnosis and patient outcomes
Addressing the Challenges of Bile Acid Diarrhea Diagnosis
A new five-metabolite blood test designed by algorithm could simplify and speed up this challenging diagnosis.
Can Ophthalmic Biomarkers Offer Insights into Brain Pathologies?
Protein levels in the vitreous humor may have the potential to support the diagnosis and staging of neurodegenerative diseases.
New Blood-Based PTSD Biomarkers Revealed
A simple blood test may help screen, identify, intervene, treat, monitor, and eventually, prevent PTSD.
New Device Predicts the Efficacy of Hypnosis Treatment for Pain
The inexpensive POC device is a biosensor that performs COMT genotyping as a biomarker for hypnotizability.
Simplifying Antidepressant Quantification in Clinical Labs
A recent study provides insights on how to use automation and only 20 μL of a serum sample to quantify blood levels of antidepressants.
Bringing Multi-Cancer Tests Closer to Reality
A new method for early detection of 14 cancer types based on glycosaminoglycan profiles shows promise.
Easier, Noninvasive Diagnosis of Neurological Disorders
More companies have begun offering neurofilament light chain blood tests as a cost-effective alternative to conventional methods.
Improving the Chances of Early Breast Cancer Detection in High-Risk Patients
A new test targeting changes in serum proteins can detect breast cancer up to two years before the condition would normally be diagnosed.
New Urine Test Can Detect Synthetic Cannabinoids in Marijuana
Recent study shows the new test can identify a widespread and dangerous class of synthetic cannabinoids called BZO-CHMOXIZID.
CMS to Create New Breakthrough Device Medicare Coverage Rule
The rule would ensure Medicare coverage of newly approved breakthrough devices, but have stricter evidence standards.
